text:
Part I Overview Information
United States Department of Health and Human Services (HHS)
Issuing Organization
National Center for Injury Prevention and Control, Centers for Disease Control and Prevention (NCIPC/CDC) at http://www.cdc.gov/ncipc/
Participating Organizations
Centers for Disease Control and Prevention (CDC) at http://www.cdc.gov/
Components of Participating Organizations
National Center for Injury Prevention and Control (NCIPC/CDC) at http://www.cdc.gov/ncipc/
Title: Youth Violence Prevention through Economic, Environmental, and Policy Change (U01)
The policies, guidelines, terms, and conditions of the HHS Centers for Disease Control and Prevention (CDC) stated in this announcement might differ from those used by the HHS National Institutes of Health (NIH). If written guidance for completing this application is not available on the CDC website, then CDC will direct applicants elsewhere for that information.
Authority: Sections 301(a) and 392(a)(3) of the Public Health Service Act (42 U.S.C. Sections 241(a) and 280b-1a, as amended.
Announcement Type: New
Instructions for Submission of Electronic Research Applications:
If you do not have access to the Internet, or if you have difficulty accessing the forms online, you may contact the CDC Procurement and Grants Office Technical Information Management Section (PGOTIMS) staff. For this, or further assistance, contact PGO TIMS: Telephone (770) 488-2700, Email: firstname.lastname@example.com.
NOTICE: Applications submitted in response to this Funding Opportunity Announcement (FOA) for Federal assistance must be submitted electronically through Grants.gov (http://www.grants.gov) using the SF424 Research and Related (R&R) forms and the SF424 (R&R) Application Guide.
This FOA must be read in conjunction with the application package instructions included with this announcement on Grants.gov/Apply for Grants (hereafter referred to as, Grants.gov/Apply.)
A registration process is necessary before submission, and applicants are strongly encouraged to start the process at least four weeks prior to the grant submission date. See Section IV.
Two steps are required for on time submission:
1) The application must be successfully received by Grants.gov no later than 5:00 p.m. Eastern Standard Time on the application submission receipt date (see �Key Dates� below).
2) Applicants must complete a verification step in the Electronic Research Administration (eRA Commons) within two business days of notification. Note: Since email can be unreliable, it is the responsibility of the applicant to periodically check on their application status in the eRA Commons.
Funding Opportunity Announcement (FOA) Number: RFA-CE-09-009
Catalog of Federal Domestic Assistance Number(s): 93.136, Injury Prevention and Control Research and State and Community Based Programs
Key Dates
Release/Posted Date:
Letter of Intent Receipt Date:
January 26, 2009.
Application Submission Receipt
February 23, 2009
Peer Review Date(s):
April � May, 2009
Council Review Date(s):
May � June 2009
Earliest Anticipated Start Date(s): September, 2009
Expiration Date: One day after application due date
Additional Information to Be Available Date: Technical assistance will be available for potential applicants during one conference call to be held on January 22, 2009 from 1:00 p.m. to 2:30 p.m. (Eastern time). The conference can be accessed by calling: 1-866-771-6423 and entering the passcode: 6139831. Questions and answers from this call will be posted with the announcement on www.grants.gov.
Due Date for E.O. 12372
Executive Order 12372 does not apply to this program.
Additional Overview Content
Executive Summary
Funding Opportunity Announcement Glossary: FOA Glossary Terminology
Table of Contents
Part I Overview Information
Part II Full Text of Announcement
Section I. Funding Opportunity Description
1. Research Objectives
Section II. Award Information
1. Mechanism(s) of Support
2. Funds Available
Section III. Eligibility Information
1. Eligible Applicants
A. Eligible Institutions
2. Cost Sharing or Matching
3. Other - Special
Eligibility Criteria
Section IV. Application and Submission Information
1. Request Application
2. Content and Form of
Application Submission
3. Submission Dates and Times
A. Receipt and Review and
Anticipated Start Dates
1. Letter of Intent
B. Submitting an
Application to CDC
C. Application Processing
4. Intergovernmental Review
5. Funding Restrictions
6. Other Submission
Section V. Application Review Information
1. Criteria
2. Review and Selection
A. Additional Review
B. Additional Review
C. Sharing Research Data
D. Sharing Research
3. Anticipated Announcement
and Award Dates
Section VI. Award Administration Information
1. Award Notices
2. Administrative and
National Policy Requirements
A. Cooperative Agreement
1. Recipient Rights
and Responsibilities
3. Collaborative
3. Reporting
Section VII. Agency Contact(s)
1. Scientific/Research
2. Peer Review Contact(s)
3. Financial/ Grants
Management Contact(s)
4. General Questions Contact(s)
Section VIII. Other Information - Required Federal Citations
Part II -
Full Text of Announcement
Section I. Funding Opportunity Description
1. Research Objectives
The National Center for Injury Prevention and Control (NCIPC) of CDC within HHS is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2010" and to measuring program performance as stipulated by the Government Performance and Review Act (GPRA). This RFA addresses �Healthy People 2010� priority area of injury and violence prevention and is in alignment with NCIPC performance goal to conduct a targeted program of research to prevent injury-related death and disability. For more information, see www.healthypeople.gov and http://intra-apps.cdc.gov/fmo/.
The purpose of this program of research is to assess the efficacy or effectiveness of interventions and policies designed to change the economic or environmental characteristics of a community to reduce rates of youth violence perpetration and victimization. Youth violence has been linked to a variety of factors, including individual, family, community, and societal characteristics. Although much research has been conducted on interventions to change the characteristics of individuals and families, less research has focused on evaluating interventions and policies designed to change community economic or environmental factors.
A number of community characteristics increase the probability of youth violence. Crime and violence tend to be high in areas in which at least 20 percent of the residents are poor (Lamison-White, 1996). These areas are often characterized by high concentrations of poverty and unemployment, high levels of residential instability, family disruption, crowded housing, drug-distribution networks, and low community participation (Sampson & Lauritsen, 1994; Tolan, Gorman-Smith, & Henry, 2003). These areas also tend to have high rates of school dropouts, high rates of substance abuse and teenage pregnancy, and a disproportionate number of households headed by women (Eller, 1996; Proctor & Dalaker, 2002; Reiss & Roth, 1993). In addition to their demographic characteristics, economically poor neighborhoods differ from more affluent neighborhoods in a number of ways. Poor neighborhoods tend to be characterized by disorganization, and as a result, frequently lack effective social controls (Chung & Steinberg, 2006; Elliot et al., 1996; Sampson, Raudenbush, & Earls, 1997). High levels of social disorganization also limit the ability of community residents to supervise and control adolescent peer groups, especially gangs (Sampson & Lauritsen, 1994).
Policies and interventions focused on addressing community characteristics associated with crime and violence have the potential to impact rates of youth violence. For example, past research suggests that policies focused on relocating disadvantaged families to more affluent neighborhoods may contribute to at least short term reductions in youth arrests for violent crime (Kling & Liebman, 2004). However, the overall benefits of relocation appear to vary for male and female youth and by the type of educational, emotional, physical, or behavioral outcome examined (Kling, Ludwig, & Katz, 2004), suggesting the need for further research to better understand the impacts of such policies and other interventions on rates of youth violence. Similarly, research suggests that modifications to the built environment, such as improvements to the pedestrian environment (e.g., lighting and improved landscaping) and architectural changes (e.g., porches, balconies, increased residential space) can contribute to relative reductions in calls to law enforcement and some crimes, such as prostitution and narcotics violations, possibly through increases in social capital and intolerance of criminal activity (Carter, Carter, & Dannenberg, 2003). However, the ability of approaches focused on changing the social and physical environment to reduce violent crime, particularly youth violence, remains unclear.
Research Objective
Research funded under this announcement is expected to further our understanding of how interventions and policies implemented to change the economic and environmental characteristics of communities can reduce violence. A clear distinction is made here between community-based interventions, which are programs that are implemented in the community and/or by a community-based organization targeting change in individual- or family-level factors (e.g., youth conflict resolution skills, parenting skills, job skills, knowledge about violence etc.), from interventions and policies targeting changes in the economic or environmental characteristics of the community, such as those described above (e.g., neighborhood or community concentrations of poverty, residential instability, neighborhood disorganization, supervision and control of adolescents, the physical environment, etc.).
The specific research objective of this program is to evaluate the efficacy or effectiveness of primary prevention interventions, programs, strategies, and policies that focus on the economic or environmental characteristics of communities rather than community-based interventions and strategies that focus on criminal justice responses (e.g., community policing, arrest strategies). The proposed research should be designed to do both of the following:
1. Detail one or more specific interventions for altering variables at the level of the community, rather than propose a process for determining which interventions are appropriate for the chosen community.
2. Assess the effects of only one strategy or policy designed to change community characteristics, not a larger multi-level intervention trial (a multi-level intervention trial is defined here as one that addresses the effects of community factors in combination with one or more components that address individual-level or family-level factors).
Multi-level intervention trials and research evaluating strategies involving community-based interventions (as described above) or interventions proposing to change only the characteristics of individuals or families will be considered non-responsive.
Strategies to address economic or environmental community characteristics include:
� Strategies to improve the physical and social characteristics of neighborhoods (e.g., through environmental design changes). Promising modifications to the physical environment include not only design elements that inhibit violence or reduce opportunities for violent behavior (e.g., natural surveillance, access management), but also use of the built environment to promote opportunities for positive social interactions and a sense of ownership, order, and belonging.
� Strategies and policies to improve financial, housing, and/or employment opportunities in impoverished areas (e.g., through economic development schemes, such as business improvement districts or other public policy initiatives, such as reforms in public assistance and housing).
� Efforts to deconcentrate areas with high rates of poverty and violence (e.g., through reforms in economic assistance programs and housing).
� Strategies or policies to increase formal and/or informal supervision of youth (e.g., through changes in school, afterschool, or other community or organizational policies and processes).
� Strategies or policies to reduce community density and availability of alcohol and drugs.
Recipients are expected to evaluate a new or an ongoing intervention or policy that targets modifiable characteristics of the community that are empirically associated with increased risk of youth violence and/or protective factors that buffer against risks for youth violence. Funds are intended to support new evaluations assessing the efficacy or effectiveness of policies and interventions on youth violence outcomes. Applicants currently evaluating interventions or policies designed to change characteristics of a community on other outcomes (e.g., drug use, physical activity etc.), as opposed to supplementing or extending data collection on youth violence outcomes already under investigation, are also encouraged to apply.
Scientific Standards
Research funded under this announcement is expected to adhere to high scientific standards, and to incorporate the following elements:
Whenever feasible, collection of information on the economic costs of the intervention or policy implementation from the programmatic and societal perspectives to perform cost analyses or other economic evaluation is encouraged. For example, it is possible to collect cost data when implementing a new intervention or policy, or it may be possible to retrospectively collect relevant data on the costs associated with implementing the intervention or policy. For effective interventions, it is possible to do cost-effectiveness studies. To be comparable to other cost-effectiveness studies, the studies should adhere to the guidelines in the following references:
Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
Haddix AC, Teutsch SM, Corso, PS. Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation. Second Edition. New York: Oxford University Press, 2003.
Section VIII, Other Information - Required Federal Citations,
for policies related to this announcement.
Section II. Award Information
1. Mechanism(s) of Support
This funding opportunity will use the U01 activity code.
The HHS/CDC U01 is a cooperative agreement assistance instrument. Under the cooperative agreement assistance instrument, the Recipient Organization retains the primary responsibility and dominant role for planning, directing, and executing the proposed project, and HHS/CDC staff is substantially involved as a partner with the Recipient Organization, as described in Section VI.2.A., "Cooperative Agreement�.
2. Funds Available
The participating Centers, Institutes, and Offices (CIOs) (NCIPC) intend to commit approximately $1,000,000 (including direct and indirect costs) in FY2009 to fund up to two awards. The average award amount will be $500,000 (including direct and indirect costs) for the first 12-month budget period. An applicant may request a project period of up to 5 years. An applicant may request up to $500,000 for the first 12-month budget period (including direct and indirect costs). An applicant may request up to $2,500,000 maximum for the entire project period. The approximate total project period funded amount is $2,500,000 per award or $5,000,000 for both awards (including direct and indirect costs). The anticipated start date for new awards is September, 2009.
All estimated funding amounts are subject to availability of funds.
Guidance for completing a detailed justified budget can be found on the CDC Website, at the following address: http://www.cdc.gov/od/pgo/funding/budgetguide.htm.
If an applicant requests a funding amount greater than the ceiling of the award range, HHS/CDC will consider the application non-responsive, and it will not enter into the review process. HHS/CDC will notify the applicant that the application did not meet the submission requirements.
Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. Although the financial plans of the CIO (s) provide support for this program, awards pursuant to this funding opportunity are contingent upon the availability of funds and the receipt of a sufficient number of meritorious applications.
Section III. Eligibility Information
1. Eligible Applicants
1.A. Eligible Institutions
You may submit an application if your organization has any of the following characteristics:
A Bona Fide Agent is an agency/organization identified by the state as eligible to submit an application under the state eligibility in lieu of a state application. If you are applying as a bona fide agent of a state or local government, you must provide a letter from the state or local government as documentation of your status. Attach this documentation behind the first page of your application form or for electronic applications, use a .pdf file and attach as �Other Documents� and label as appropriate.
2. Cost Sharing or Matching
Cost sharing, matching, or cost participation is not
The most current HHS Grants Policy Statement is available at:
3. Other-Special Eligibility Criteria
If your application is incomplete or non-responsive to the special requirements listed in this section, it will not be entered into the review process.
To be considered responsive to this announcement, the principal investigator (on behalf of the applicant institution) must provide:
Note: Title 2 of the United States Code Section 1611 states that an organization described in Section 501(c)(4) of the Internal Revenue Code that engages in lobbying activities is not eligible to receive Federal funds constituting an award, grant, or loan.
Section IV. Application and Submission Information
To download a SF424 (R&R) Application Package and SF424 (R&R) Application Instructions for completing the SF424 (R&R) forms for this FOA, link to Grants.gov/Apply and follow the directions provided on that Web site.
A one-time registration is required for institutions/organizations at the following:
� Grants.gov Get Registered, http://www.grants.gov/applicants/get_registered.jsp � eRA Commons Prepare to Apply, http://era.nih.gov/ElectronicReceipt/preparing.htmIMPORTANT: both the applicant organization, as well as the PD/PI must register in eRA Commons for an application to be accepted electronically. The Credentials Log-In, referenced in Section IV. 2. Content and Form of Application Submission, is obtained through Step #3 in the required actions below.
PD/PIs should work with their institutions/organizations to make sure they are registered in the eRA Commons.
The following three steps are required before an applicant institution/organization can submit an electronic application, as follows:
1) Organizational/Institutional Registration in Grants.gov Get Registered, http://www.grants.gov/applicants/get_registered.jsp
� Your organization will need to obtain a Data Universal Number System (DUNS) number and register with the Central Contractor Registration (CCR) as part of the Grants.gov registration process. � If your organization does not have a Taxpayer Identification Number (TIN) or Employer Identification Number (EIN), allow for extra time. A valid TIN or EIN is necessary for CCR registration. � The CCR also validates the EIN against Internal Revenue Service records, a step that will take an additional one to two business days. � If Foreign Institutions are listed in Section III.1.A. Eligible Institutions, include the following bullet: Applicants outside the US are required to include a NATO Commercial and Government Entity (NCAGE) number on their CCR registration. See section IV.2. Content and Form of Application Submission, for instructions. � Direct questions regarding Grants.gov registration to:2) Organizational/Institutional Registration in the eRA Commons Prepare to Apply, http://era.nih.gov/ElectronicReceipt/preparing.htm
� To find out if an organization is already eRA Commons-registered, see the "List of Grantee Organizations Registered in eRA Commons.� � Direct questions regarding the eRA Commons registration to:3) Project Director/Principal Investigator (PD/PI) Registration in the eRA Commons: Refer to the NIH eRA Commons System (COM) Users Guide.
Note that if a PD/PI is also an HHS peer-reviewer with an Individual DUNS and CCR registration, that particular DUNS number and CCR registration are for the individual reviewer only. These are different than any DUNS number and CCR registration used by an applicant organization. Individual DUNS and CCR registration should be used only for the purposes of personal reimbursement and should not be used on any grant applications submitted to the Federal Government.
Several of the steps of the registration process could take four weeks or more. Therefore, applicants should immediately check with their business official to determine whether their organization/institution is already registered in both Grants.gov and the eRA Commons. The HHS/CDC strongly encourages applicants to use the Grants.gov electronic applications process and have organizations and PD/PIs complete all necessary registrations.
1. Request Application Information
Applicants must download
the SF424 (R&R) application forms and SF424 (R&R)
Application Guide for this FOA through
Note: Only the forms package directly attached to a specific
FOA can be used. You will not be able to use any other SF424
(R&R) forms (e.g., sample forms, forms from another FOA)
although some of the "Attachment" files may be useable for
more than one FOA.
If you do not have access to the Internet, or if you have difficulty accessing the forms online, you may contact the CDC Procurement and Grants Office Technical Information Management Section (PGOTIMS) staff. For this, or further assistance, contact PGO TIMS: Telephone (770) 488-2700, Email: firstname.lastname@example.com.
Telecommunications for the
hearing impaired: TTY 770-488-2783.
Content and Form of Application Submission
Prepare all applications using the SF424 (R&R) application forms and in accordance with the SF424 (R&R) Application Guide (MS Word or PDF).
The SF424 (R&R) Application Guide is critical to submitting a complete and accurate application to HHS/CDC. There are fields within the SF424 (R&R) application components that, although not marked as mandatory, are required by HHS/CDC (e.g., the �Credential� log-in field of the �Research & Related Senior/Key Person Profile� component must contain the PD/PI assigned eRA Commons User ID). Agency-specific instructions for such fields are clearly identified in the Application Guide. For additional information, see �Tips and Tools for Navigating Electronic Submission� on the front page of �Electronic Submission of Grant Applications.�
In addition to the instructions provided in the SF424 (R&R) for writing the Project Summary/Abstract, structure the Project Summary/Abstract using the following components: (1) statement of the problem, (2) purpose of the proposed research, (3) methods, including study population, data sources and any statistical analyses to be performed, and (4) implications for prevention.
The Project Summary/Abstract should :
� State the hypotheses � Describe the objectives and specific aims � State the importance of the research and how it is innovative � Outline the methods that will be used to accomplish the goals � Use language that is simple and easy to understand for a broad audienceYou must include a research plan with your application. Your research plan should address activities to be conducted over the entire project period.
The SF424 (R&R) application is comprised of data arranged in separate components. Some components are required, others are optional. The forms package associated with this FOA in Grants.gov/APPLY will include all applicable components, mandatory and optional. A completed application in response to this FOA will include the following components:
Required Components:
SF424 (R&R) (Cover component)
SF424 Form Project Summary/Abstract
PHS398 Cover Letter File
Research & Related
Subaward Budget Attachment(s) Form
Note: While both
budget components are included in the SF424 (R&R) forms
package, the CDC
(activity code) uses ONLY the detailed
Research & Related
Budget. (Do not use the PHS 398
Modular Budget.) A
detailed budget justification prepared using CDC Budget
Guidance (http://www.cdc.gov/od/pgo/funding/grants/Budget_Guidelines.doc)
must be submitted with the application.
3. Submission Dates and Times
See Section IV.3.A for details
3.A. Submission,
Review and Anticipated Start Dates
Letter of Intent Receipt Date:
January 26, 2009.
Application Submission Receipt
February 23, 2009.
Peer Review Date(s): April
- May, 2009
Council Review Date(s): May � June 2009
Earliest Anticipated Start Date(s): September, 2009
3.A.1. Letter of Intent
Prospective applicants are asked to submit a letter of intent that includes the following information:
� Descriptive title of proposed research. � Name, address, and telephone number of the Principal Investigator. � Names of other key personnel. � Participating institutions. � Number and title of this funding opportunity
Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows CDC Program staff to estimate the potential review workload and plan the review.
The letter of intent is to be sent by the date listed in Section IV.3.A
The letter of intent should be sent by mail, fax or email to:
NCIPC Extramural Resources Team
CDC, National Center for Injury Prevention and Control
Address for Express Mail or Delivery Service:
4770 Buford Hwy NE
Bldg 106, 9th Floor, Room 09.008
Atlanta, GA 30341
Address for U.S. Postal Service Mail:
4770 Buford Hwy NE, Mailstop F-63
Atlanta, GA 30341
Telephone: (770) 488-4037
3.B. Submitting an Application to CDC
If the instructions in this announcement differ in any way from the SF424 R&R instructions, follow the instructions in this announcement.
To submit an application in response to this FOA, applicants should access this FOA via http://www.grants.gov/Apply and follow steps 1-4. If submittal of the application is done electronically through Grants.gov (http://www.grants.gov), the application will be electronically time/date stamped by Grants.gov. The applicants� Authorized Organization Representative (AOR) will receive an e-mail notice of receipt from eRA Commons and Grants.gov when HHS/CDC receives the application.
This announcement is the definitive guide on Letter Of Intent (LOI) and application content, submission address, and deadline. It supersedes information provided in the application instructions. If your application does not meet the deadline described in Section IV.3.A, it will not be eligible for review, and HHS/CDC will discard it. You will receive notification that you did not meet the submission requirements.
If you still have a question, contact the PGO-TIMS staff at:
770-488-2700. Before calling, please wait two to three days
after the submission deadline. This will allow time for HHS/CDC
to process and log submissions.
Technical Information Management Section � RFA-CE-09-009
CDC, Procurements and Grants Office
U.S. Department of Health and Human Services
2920 Brandywine Road
Atlanta, GA 30341
Phone: 770-488-2700 EST
Application Processing
HHS/CDC must receive applications
on or before 5:00 P.M. Eastern Standard Time on the
application submission date(s) described above (Section
IV.3.A.). If HHS/CDC receives an application after that
submission date and time, the application may be delayed in
the review process or not reviewed.
Once an application package has been successfully submitted through Grants.gov, any errors have been addressed, and the assembled application has been created in the eRA Commons, the PD/PI and the Authorized Organization Representative/Signing Official (AOR/SO) have two business days to view the application image.
� If everything is acceptable, no further action is necessary. The application will automatically move forward for processing by the CDC, PGO, Technical Information Management Section, after two business days.
� Prior to the submission deadline, the AOR/SO can �Reject� the assembled application and submit a changed/corrected application within the two day viewing window. This option should be used if the AOR/SO determines that warnings should be addressed. Reminder: warnings do not stop further application processing. If an application submission results in warnings (but no errors) it will automatically move forward after two business days if no action is taken. Please remember that some warnings may not be applicable or may need to be addressed after application submission.
� If the two day window falls after the submission deadline, the AOR/SO will have the option to �Reject� the application if, due to an eRA Commons or Grants.gov system issue, the application does not correctly reflect the submitted application package (e.g., some part of the application was lost or didn�t transfer correctly during the submission process). The AOR/SO should first contact the eRA Commons Helpdesk to confirm the system error, document the issue, and determine the best course of action. HHS/CDC will not penalize the applicant for an eRA Commons or Grants.gov system issue.
� If the AOR/SO chooses to �Reject� the image after the submission deadline for a reason other than an eRA Commons or Grants.gov system failure, a changed/corrected application still can be submitted but it will be subject to the CDC late policy guidelines and may not be accepted. The reason for this delay should be explained in the cover letter attachment and must refer only to Commons errors and/or technical errors.
� Both the AOR/SO and PD/PI will receive e-mail notifications when the application is rejected or the application automatically moves forward in the process after two days.
Upon receipt, applications will be evaluated for completeness and responsiveness by NCIPC and HHS/CDC Procurement and Grants Office (PGO). HHS/CDC will not review incomplete and non-responsive applications.
There will be an acknowledgement of receipt of applications from Grants.gov and the eRA Commons.
4. Intergovernmental Review
Executive Order 12372 does not apply to this program.
Additional guidance can be found at HHS Grants Policy Statement.
5. Funding Restrictions
All HHS/CDC awards are
subject to the terms and conditions, cost principles, and
other considerations described in the HHS Grants Policy
Restrictions, which applicants must take into account while writing their budgets, are as follows:
6. Other Submission Requirements
Awardees, upon acceptance of Notice of Award (NoA), must agree to the "Cooperative Agreement Terms and Conditions of Award" in Section VI. "Award Administration Information.�
Travel costs for up to two people including the PI for one reverse site visit to HHS/CDC in Atlanta on an annual basis should be included.
If you are requesting indirect costs in your budget, you must include a copy of your indirect cost rate agreement. If your indirect cost rate is a provisional rate, the agreement should be less than 12 months of age. If submitting electronically, use a PDF version of the agreement, attach it in Grants.gov under �Other Attachments�, and title it appropriately.
Applicants� research plan(s) should address activities they will conduct over the entire project period.
The HHS/CDC requires the PD/PI to fill in his/her eRA Commons User ID in the �PROFILE � Project Director/Principal Investigator� section, �Credential� log-in field of the �Research & Related Senior/Key Person Profile� component. The applicant organization must include its DUNS number in its Organizational Profile in the eRA Commons. This DUNS number must match the DUNS number provided at CCR registration with Grants.gov. For additional information, see Registration FAQs � Important Tips � Electronic Submission of Grant Applications.
Research Plan Component Sections
While each section of the Research Plan component needs to be uploaded separately as a .pdf attachment, applicants are encouraged to construct the Research Plan component as a single document, separating sections into distinct .pdf attachments just before uploading the files. This approach will enable applicants to better monitor formatting requirements such as page limits. All attachments must be provided to HHS/CDC in .pdf format, filenames must be included with no spaces or special characters, and a .pdf extension must be used. Do not include any information in a header or footer of the attachments. A header will be system-generated that references the PD/PI. Page numbers for the footer will be system-generated in the complete application, with all pages sequentially numbered; therefore, do not number the pages of your attachments. Your research plan must not exceed 25 pages. If your research plan exceeds the page limitation, your application may be considered unresponsive and ineligible for review.
The following materials may be included in the Appendix:
Up to 5 publications, manuscripts (accepted for publication), abstracts, patents, or other printed materials directly relevant to the proposed project. Do not include manuscripts submitted for publication. Applicants should refer to instruction guides and specific Funding Opportunity Announcements (FOAs) to determine the appropriate limit on the number of publications that may be submitted for a particular program. Note that not all grant activity codes allow the inclusion of publications.
Please note the following restriction on appendix attachments: The Research Plan Appendix attachments are limited to 10 attachments. Appendices are uploaded as attachments in the PHS 398 Research Plan form, in field #18, within the electronic application package. An applicant will receive an error message if the number of appendix attachments exceeds 10, which will result in an unsuccessful submission of the application. You may include more than one publication, or other allowable appendix material, within one attachment; however, do not let your attachments exceed 10.
Do not use the Appendix to circumvent the page limitations of the Research Plan component. An application that does not observe the relevant policies and procedures may not be considered in the review process. Applicants are reminded to review specific FOAs for any additional program-specific guidance on Appendix material and other application requirements.
Plan for Sharing Research Data
Note: HHS/CDC normally requires a plan for sharing research data. However, only proposals submitted to NCIPC for individual research projects of $500,000 or more in total (direct and indirect) costs per year require the applicant to include a data-sharing plan. If an applicant proposes a total budget that is below $500,000 then a data sharing plan is not required and the HHS/CDC steps outlined in this section do not apply.
The precise content of the data-sharing plan will vary, depending on the data being collected and how the investigator is planning to share the data. Applicants should describe briefly the expected schedule for data sharing, the format of the final dataset, the documentation to be provided, whether or not any analytic tools also will be provided, whether or not a data-sharing agreement will be required and, if so, a brief description of such an agreement (including the criteria for deciding who can receive the data and whether or not the awardee will place any conditions on their use), and the mode of data sharing (e.g., under their own auspices by mailing a disk or posting data on their institutional or personal website, through a data archive or enclave). References to data sharing may also be appropriate in other sections of the application.
All applicants must include a plan for sharing research data
in their application. The data sharing policy is available
http://www.cdc.gov/od/pgo/funding/ARs.htm under
Additional Requirements 25 Release and Sharing of Data. All
investigators responding to this funding opportunity should
include a description of how final research data will be
shared, or explain why data sharing is not possible.
The reasonableness of the
data sharing plan or the rationale for not sharing research
data will be assessed by the reviewers. However, reviewers
will not factor the proposed data sharing plan into the
determination of scientific merit or the priority score.
Awardees must agree to
Section VI.2.A., "Cooperative Agreement.�
Sharing Research Resources
Not applicable
Section V. Application Review Information
1. Criteria
Only the review criteria described below will be considered in the review process.
� Scientific merit of the proposed project as determined by peer review � Availability of funds � Relevance of program priorities and the priorities of the U.S. Department of Health and Human Services. � Applications that do not address the objectives listed in Part II, Section 1 Research Objectives, will not be funded even if they rank higher than other applications that address the required objectives.
2. Review and Selection Process
Applications that are
complete and responsive to the RFA will be evaluated for
scientific and technical merit by an appropriate peer review
group convened by NCIPC in accordance with the review
criteria stated below.
As part of the initial merit
review, all applications will:
Receive a second level of review by NCIPC Board of Scientific Counselors (BSC) to make funding recommendations based on responsiveness of applications to program priorities as stated in this FOA, Section V.1. Criteria. BSC members will vote, in a closed session, on funding recommendations. The secondary review committee has the latitude to recommend to the HHS/CDC/NCIPC Director to reach over better ranked proposals in order to assure maximum impact and balance of proposed research.
The goals of HHS/CDC-supported research are to advance the understanding of health promotion and the prevention of disease, injury, and disability, and enhance preparedness. In the written comments, evaluate the application to judge the likelihood the proposed research will have a substantial impact on the pursuit of these goals. Each of these criteria will be addressed by the reviewers and considered in assigning the overall score, weighting them as appropriate for each application.
Note that an application does not need to be strong in all
categories to be judged likely to have major scientific
impact and thus deserve a high priority score. For example,
an investigator may propose to carry out important work that
by its nature is not innovative but is essential to move a
field forward.
Does this study address an important problem? If the
applicant achieves the aims of the application, how will it
advance scientific knowledge or clinical practice? What will
be the effect of these studies on the concepts, methods,
technologies, treatments, or preventative interventions that
drive this field?
Approach: Are the conceptual or clinical framework, design, methods, and analyses adequately developed, well integrated, well reasoned, and appropriate to the aims of the project? Does the applicant acknowledge potential problem areas and consider alternative tactics? Does the applicant address the research objectives as stated in Section I? Are the targeted community characteristics and youth violence outcomes clearly described and appropriate? Is the potential effectiveness of the proposed intervention to change community characteristics and thereby reduce youth violence theoretically justified and supported with epidemiologic, methodological, and behavioral research? If the proposal includes implementation in addition to evaluation, how feasible is the implementation of the intervention or policy as proposed? Can the intervention reasonably be predicted to produce the expected reductions in youth violence? Is the setting for implementation appropriate? Does the research design allow for a rigorous examination of the effectiveness of the intervention or policy in reducing youth violence, including assessment of relative change in youth violence over time? Are descriptions of sampling methods, sample size and power estimates, and data collection measures well described, justified, and do they adequately address the central research question in the announcement? Are plans for assessing implementation processes and fidelity clear and appropriate? Does the applicant provide a strong rationale for why an economic evaluation can not be conducted or provide an appropriate plan for conducting an economic evaluation? Does the applicant provide evidence supporting their ability to access relevant data?
Is the project original and innovative? For example: Does
the project challenge existing paradigms or clinical
practice; address an innovative hypothesis or critical
barrier to progress in the field? Does the project develop
or employ novel concepts, approaches, methodologies, tools,
or technologies for this area?
Investigators: Are the investigators appropriately trained and well suited to carry out this work? Is the work proposed appropriate to the experience level of the principal investigator and other researchers? Does the investigative team bring complementary and integrated expertise to the project (if applicable)?
Environment: Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed studies benefit from unique features of the scientific environment, or subject populations, or employ useful collaborative arrangements? Is there evidence of institutional support? If collaborations are being proposed, are the partners and their skills and expertise well described? Can proposed collaborations reasonably be expected to improve the quality of the implementation and evaluation of the intervention or policy? Does the applicant have appropriate access to the target community?
2.A. Additional
Review Criteria
In addition to the above
criteria, the following items will continue to be considered
in the determination of scientific merit and the priority
Application Review
HHS/CDC/NCIPC will withdraw from further consideration applications judged to be noncompetitive and promptly notify the principal investigator/program director and the official signing for the applicant organization.
The secondary review will be conducted by the Board of Scientific Counselors (BSC).
The BSC committee�s responsibility is to develop funding recommendations for the HHS/CDC/NCIPC Director based on the results of the primary review, the relevance and balance of proposed research relative to the HHS/CDC/NCIPC programs and priorities, and to assure that unwarranted duplication of federally-funded research does not occur. The secondary review committee has the latitude to recommend to the HHS/CDC/NCIPC Director to reach over better ranked proposals in order to assure maximum impact and balance of proposed research. The factors to be considered will include:
� The comments and recommendations of the primary review including the application�s priority score as the primary factor in the selection process. � The relevance and balance of proposed research relative to the HHS/CDC/NCIPC programs priorities and the research objectives identified in this FOA.
Protection of Human Subjects from Research Risk: When human subjects are involved, HHS/CDC will assess the available protections from research risk that relate to their participation in the proposed research [see the Research Plan, Section 2, item 8 on Human Subjects in the SF424 (R&R)] located at, http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm. Additional HHS/CDC Requirements under AR-1 Human Subjects Requirements are available on the Internet at the following address: http://www.cdc.gov/od/pgo/funding/ARs.htm.
Inclusion of Women and Minorities in Research:
Does the application adequately address the HHS/CDC Policy requirements regarding the inclusion of women, ethnic, and racial groups in the proposed research? This includes: (1) The proposed plan for the inclusion of both sexes and racial and ethnic minority populations for appropriate representation; (2) The proposed justification when representation is limited or absent; (3) A statement as to whether the design of the study is adequate to measure differences when warranted; and (4) A statement as to whether the plans for recruitment and outreach for study participants include the process of establishing partnerships with community(ies) and recognition of mutual benefits (see Section 2, item 9 Inclusion or Women and Minorities of the Research Plan component of the SF424 (R&R).
Inclusion of children as participants in research involving human subjects:
Does the application adequately address the HHS/CDC Policy requirements regarding the inclusion of children (i.e., individuals under the age of 21) in the proposed research? This includes: (1) The proposed plan to include child populations for appropriate representation; (2) The proposed justification when representation is limited or absent (see Section 2, item 10, Inclusion of Children of the Research Plan component of the SF424 (R&R).
Additional Review Considerations
Budget and Period of
Support: The
reasonableness of the proposed budget and the
appropriateness of the requested period of support in
relation to the proposed research may be assessed by the
reviewers. Is the number of person months listed for the
effort of the PD/PI appropriate for the work proposed? Is
each budget category realistic and justified in terms of the
aims and methods? The evaluation of the budget should not
affect the priority score.
Sharing Research Data
Data Sharing Plan: HHS/CDC will assess the reasonableness of the data sharing plan. However, reviewers will not factor the proposed data sharing plan into the determination of scientific merit or the priority score. The presence of a data sharing plan will be part of the terms and conditions of the award. The funding organization will be responsible for monitoring the data sharing policy. Program staff will be responsible for the administrative review of the plan for sharing research data.
2.D. Sharing
Research Resources
Not applicable.
Anticipated Announcement and Award Dates
Grantees will be notified in September 2009 by HHS/CDC�s
Procurement and Grants Office (PGO) if their applications
were selected for funding.
Section VI. Award Administration Information
1. Award Notices
After the peer review of the
application is completed, the applicant organization will
receive a written critique called a �Summary Statement.�
The applicant organization and the PD/PI will be able to
access the Summary Statement via the eRA Commons.
HHS/CDC will contact those
applicants under consideration for funding for additional
A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization. The NoA signed by the Grants Management Officer (GMO) is the authorizing document. HHS/CDC will mail and/or e-mail this document to the recipient fiscal officer identified in the application.
Selection of the application for award is not an authorization to begin performance. Any cost incurred before receipt of the NoA is at the recipient�s risk. These costs may be reimbursed only to the extent considered allowable pre-award costs. See also Section IV.5. Funding Restrictions.
CDC may grant expanded authority to eligible grantees under this announcement.
2. Administrative and National Policy Requirements
The Code of Federal Regulations 45 CFR Part 74 and Part 92 have details about policy requirements. For more information on the Code of Federal Regulations, see the National Archives and Records Administration at the following Internet address: http://www.access.gpo.gov/nara/cfr/cfr-table-search.html. Additional requirements are available in Section VIII. Other Information on this document or on the CDC website at the following Internet address: http://www.cdc.gov/od/pgo/funding/ARs.htm. These will be incorporated into the NoA by reference.
The following terms and conditions will be incorporated into
the NoA and will be provided to the appropriate
institutional official and a courtesy copy to the PD/PI at
the time of award.
Cooperative Agreement
The following terms of award are in addition to, and not in
lieu of, otherwise applicable Office of Management and
Budget (OMB) administrative guidelines, HHS grant
administration regulations at 45 CFR Parts 74 and 92 (Part
92 is applicable when State and local Governments are
eligible to apply), and other HHS/CDC grant administration
The administrative and funding
instrument used for this program will be the cooperative
agreement U01, an "assistance" instrument (rather
than an "acquisition" instrument) in which substantial
HHS/CDC programmatic involvement with the awardees is
anticipated during the performance of the activities. Under
the cooperative agreement, the HHS/CDC purpose is to support
and stimulate the recipients' activities by involvement in,
and otherwise working jointly with, the award recipients in
a partnership role; it is not to assume direction, prime
responsibility, or a dominant role in the activities.
Consistent with this concept, the dominant role and prime
responsibility resides with the awardees for the project as
a whole; although specific tasks and activities may be
shared among the awardees and the HHS/CDC may share specific
tasks and activities, as defined above.
2.A.1. Recipient Rights and
The Recipient will have the primary responsibility for the following:
Additionally, an HHS/CDC
agency program official or CIO program director will be
responsible for the normal scientific and programmatic
stewardship of the award and will be named in the NoA.
Recipient Organization must provide HHS/CDC with an original, plus two hard copies of the following reports:
1. Non-Competing Grant Progress Report, (use form PHS 2590, posted on the HHS/CDC website, http://www.cdc.gov/od/pgo/funding/forms.htm and at http://grants.nih.gov/grants/funding/2590/2590.htm, no less than 120 days prior to the end of the current budget period. The progress report will serve as the non-competing continuation application. If you would like to change reporting requirement (i.e. quarterly, semi annual) see instructions above and insert. Add Information Here.
2. Annual progress report is due 90 days after the end of the budget period.
3. Financial status report, no more than 90 days after the end of the budget period.
4. Final financial and performance reports, no more than 90 days after the end of the project period/budget year.
Recipient Organization must forward these reports by the U.S. Postal Service or express delivery to the Grants Management Specialist listed in the �Agency Contacts� section of this FOA.
Although the financial plans of the HHS/CDC CIO(s) provide support for this program, awards pursuant to this funding opportunity are contingent upon the availability of funds, evidence of satisfactory progress by the recipient (as documented in required reports) and the determination that continued funding is in the best interest of the Federal government.
Section VII. Agency Contacts
encourages your inquiries concerning this FOA and welcomes
the opportunity to answer questions from potential
applicants. Inquiries can fall into three areas:
scientific/research, peer review, and financial or grants
management issues:
Scientific/Research Contacts:
Joanne Klevens, M.D., Ph.D.
Division of Violence Prevention (DVP)
National Center for Injury Prevention and Control
Centers for Disease Control and Prevention (CDC)
U.S. Department of Health and Human Services
4770 Buford Hwy, NE, Mailstop F-63
Atlanta, GA 30341
Telephone: (770) 488-1386
2. Peer Review Contacts:
Felix Rogers, Ph. D.
Scientific Review Administrator
National Center for Injury Prevention and Control
Centers for Disease Control and Prevention (CDC)
U.S. Department of Health and Human Services
4770 Buford Hwy, NE, Mailstop F-62
Atlanta, GA 30341
Telephone: (770) 488-4334
3. Financial or Grants Management Contacts:
Barbara R. Benyard
Procurement and Grants Office
Centers for Disease Control and Prevention
U.S. Department of Health and Human Services
2920 Brandywine Road, MS-K-70
Atlanta, GA 30341
Telephone: (770) 488-2757
General Questions Contacts:
Technical Information
Management Section
CDC Procurement and Grants Office
U.S. Department of Health and Human Services
2920 Brandywine Road
Atlanta, GA 30341
Telephone: 770-488-2700
Email: email@example.com
5. Special Guidelines for Technical Assistance:
NCIPC Website: For additional help in preparing your grant application please see the �frequently asked questions� section on the NCIPC webpage at:
Additional Information to Be Available Date: Technical assistance will be available for potential applicants during one conference call to be held on January 22, 2009 from 1:00 p.m. to 2:30 p.m. (Eastern time). The conference can be accessed by calling: 1-866-771-6423 and entering the passcode: 6139831.
Section VIII. Other Information
Required Federal Citations
Human Subjects Protection:
regulations (45 CFR Part 46)
require that applications
and proposals involving human subjects must be evaluated
with reference to the risks to the subjects, the adequacy of
protection against these risks, the potential benefits of
the research to the subjects and others, and the importance
of the knowledge gained or to be gained (http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm).
Additional HHS/CDC Requirements under AR-1 Human Subjects
Requirements can be found on the Internet at the following
Requirements for Inclusion
of Women and Racial and Ethnic Minorities in Research
It is the policy of the Centers for Disease Control and Prevention (CDC) and the Agency for Toxic Substances and Disease Registry (ATSDR) to ensure that individuals of both sexes and the various racial and ethnic groups will be included in CDC/ATSDR-supported research projects involving human subjects, whenever feasible and appropriate. Racial and ethnic groups are those defined in OMB Directive No. 15 and include American Indian or Alaska Native, Asian, Black or African American, Hispanic or Latino, Native Hawaiian or Other Pacific Islander. Applicants shall ensure that women, racial and ethnic minority populations are appropriately represented in applications for research involving human subjects. Where clear and compelling rationale exist that inclusion is inappropriate or not feasible, this situation must be explained as part of the application. This policy does not apply to research studies when the investigator cannot control the race, ethnicity, and/or sex of subjects. Further guidance to this policy is contained in the Federal Register, Vol. 60, No. 179, pages 47947-47951, and dated Friday, September 15, 1995.
The policy of CDC is that persons under the age of 21 must
be included in all human subjects research that is conducted
or supported by CDC, unless there are scientific and ethical
reasons not to include them. This policy applies to all
CDC-conducted or CDC-supported research involving human
subjects, including research that is otherwise exempt in
accordance with Sections 101(b) and 401(b) of
45 C.F.R. Part 46, HHS Policy for the Protection of Human
Subjects. Therefore, proposals for research
involving human subjects must include a description of plans
for including persons under the age of 21. If persons under
the age of 21 will be excluded from the research, the
application or proposal must present an acceptable
justification for the exclusion.
In an extramural research plan, the investigator should create a section titled "Participation of persons under the age of 21." This section should provide either a description of the plans to include persons under the age of 21 and a rationale for selecting or excluding a specific age range, or an explanation of the reason(s) for excluding persons under the age of 21 as participants in the research. When persons under the age of 21 are included, the plan must also include a description of the expertise of the investigative team for dealing with individuals at the ages included, the appropriateness of the available facilities to accommodate the included age groups, and the inclusion of a sufficient number of persons under the age of 21 to contribute to a meaningful analysis relative to the purpose of the study. Scientific review groups at CDC will assess each application as being acceptable or unacceptable in regard to the age-appropriate inclusion or exclusion of persons under the age of 21 in the research project, in addition to evaluating the plans for conducting the research in accordance with these provisions.
The inclusion of children (as defined by the applicable law of the jurisdiction in which the research will be conducted) as subjects in research must be in compliance with all applicable subparts of 45 C.F.R. Part 46, as well as with other pertinent federal laws and regulations.
The policy of inclusion of persons under the age of 21 in CDC-conducted or CDC-supported research activities in foreign countries (including collaborative activities) is the same as that for research conducted in the United States.
Paperwork Reduction Act Requirements
Under the Paperwork Reduction Act, projects that involve the collection of information from 10 or more individuals and funded by a grant or a cooperative agreement will be subject to review and approval by the Office of Management and Budget (OMB).
Smoke-Free Workplace Requirements
CDC strongly encourages all recipients to provide a smoke-free workplace and to promote abstinence from all tobacco products. Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities that receive Federal funds in which education, library, day care, health care, or early childhood development services are provided to children.
Healthy People 2010
The Public Health Service (PHS) is committed to achieving
the health promotion and disease prevention objectives of
"Healthy People 2010," a PHS-led national activity for
setting priority areas. This PA is related to one or more of
the priority areas. Potential applicants may obtain a copy
of "Healthy People 2010" at
Lobbying Restrictions
Applicants should be aware of restrictions on the use of HHS funds for lobbying of Federal or State legislative bodies. Under the provisions of 31 U.S.C. Section 1352, recipients (and their sub-tier contractors) are prohibited from using appropriated Federal funds (other than profits from a Federal contract) for lobbying congress or any Federal agency in connection with the award of a particular contract, grant, cooperative agreement, or loan. This includes grants/cooperative agreements that, in whole or in part, involve conferences for which Federal funds cannot be used directly or indirectly to encourage participants to lobby or to instruct participants on how to lobby.
In addition no part of CDC appropriated funds, shall be used, other than for normal and recognized executive-legislative relationships, for publicity or propaganda purposes, for the preparation, distribution, or use of any kit, pamphlet, booklet, publication, radio, television, or video presentation designed to support or defeat legislation pending before the Congress or any State or local legislature, except in presentation to the Congress or any State or local legislature itself. No part of the appropriated funds shall be used to pay the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence legislation or appropriations pending before the Congress or any State or local legislature.
Any activity designed to influence action in regard to a particular piece of pending legislation would be considered "lobbying." That is lobbying for or against pending legislation, as well as indirect or "grass roots" lobbying efforts by award recipients that are directed at inducing members of the public to contact their elected representatives at the Federal or State levels to urge support of, or opposition to, pending legislative proposals is prohibited. As a matter of policy, HHS/CDC extends the prohibitions to lobbying with respect to local legislation and local legislative bodies.
The provisions are not intended to prohibit all interaction with the legislative branch, or to prohibit educational efforts pertaining to public health. Clearly there are circumstances when it is advisable and permissible to provide information to the legislative branch in order to foster implementation of prevention strategies to promote public health. However, it would not be permissible to influence, directly or indirectly, a specific piece of pending legislation
It remains permissible to use HHS/CDC funds to engage in activity to enhance prevention; collect and analyze data; publish and disseminate results of research and surveillance data; implement prevention strategies; conduct community outreach services; provide leadership and training, and foster safe and healthful environments.
Recipients of HHS/CDC grants and cooperative agreements need to be careful to prevent CDC funds from being used to influence or promote pending legislation. With respect to conferences, public events, publications, and "grassroots" activities that relate to specific legislation, recipients of HHS/CDC funds should give close attention to isolating and separating the appropriate use of HHS/CDC funds from non-CDC funds. HHS/CDC also cautions recipients of HHS/CDC funds to be careful not to give the appearance that HHS/CDC funds are being used to carry out activities in a manner that is prohibited under Federal law.
Prohibition on Use of CDC Funds for Certain Gun Control Activities
The Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act specifies that: "None of the funds made available for injury prevention and control at the Centers for Disease Control and Prevention may be used to advocate or promote gun control."
Anti-Lobbying Act requirements prohibit lobbying Congress with appropriated Federal monies. Specifically, this Act prohibits the use of Federal funds for direct or indirect communications intended or designed to influence a member of Congress with regard to specific Federal legislation. This prohibition includes the funding and assistance of public grassroots campaigns intended or designed to influence members of Congress with regard to specific legislation or appropriation by Congress.
In addition to the restrictions in the Anti-Lobbying Act, HHS/CDC interprets the language in the HHS/CDC's Appropriations Act to mean that HHS/CDC's funds may not be spent on political action or other activities designed to affect the passage of specific Federal, State, or local legislation intended to restrict or control the purchase or use of firearms.
Accounting System Requirements
The services of a certified public accountant licensed by the State Board of Accountancy or the equivalent must be retained throughout the project as a part of the recipient's staff or as a consultant to the recipient's accounting personnel. These services may include the design, implementation, and maintenance of an accounting system that will record receipts and expenditures of Federal funds in accordance with accounting principles, Federal regulations, and terms of the cooperative agreement or grant.
Capability Assessment
It may be necessary to conduct an on-site evaluation of some applicant organization's financial management capabilities prior to or immediately following the award of the grant or cooperative agreement. Independent audit statements from a Certified Public Accountant (CPA) for the preceding two fiscal years may also be required.
Proof of Non-profit Status
Proof of nonprofit status must be submitted by private nonprofit organizations with the application. Any of the following is acceptable evidence of nonprofit status: (a) a reference to the applicant organization's listing in the Internal Revenue Service's (IRS) most recent list of tax-exempt organizations described in section 501(c)(3) of the IRS Code; (b) a copy of a currently valid IRS tax exemption certificate; (c) a statement from a State taxing body, State Attorney General, or other appropriate State Official certifying that the applicant organization has a nonprofit status and that none of the net earnings accrue to any private shareholders or individuals; (d) a certified copy of the organization's certificate of incorporation or similar document that clearly establishes nonprofit status; (e) any of the above proof for a State or national parent organization and a statement signed by the parent organization that the applicant organization is a local nonprofit affiliate.
Research Integrity
The signature of the institution official on the face page of the application submitted under this Funding Opportunity Announcement is certifying compliance with the Department of Health and Human Services (DHHS) regulations in Title 42 Part 93, Subparts A-E, entitled PUBLIC HEALTH SERVICE POLICIES ON RESEARCH MISCONDUCT.
The regulation places requirements on institutions receiving or applying for funds under the PHS Act that are monitored by the DHHS Office of Research Integrity (ORI) (http://ori.hhs.gov./policies/statutes.shtml).
For example:
Section 93.301 Institutional assurances. (a) General policy. An institution with PHS supported biomedical or behavioral research, research training or activities related to that research or research training must provide PHS with an assurance of compliance with this part, satisfactory to the Secretary. PHS funding components may authorize [[Page 28389]] funds for biomedical and behavioral research, research training, or activities related to that research or research training only to institutions that have approved assurances and required renewals on file with ORI. (b) Institutional Assurance. The responsible institutional official must assure on behalf of the institution that the institution-- (1) Has written policies and procedures in compliance with this part for inquiring into and investigating allegations of research misconduct; and (2) Complies with its own policies and procedures and the requirements of this part.
Compliance with Executive Order 13279
Faith-based organization are eligible to receive federal financial assistance, and their applications are evaluated in the same manner and using the same criteria as those for non-faith-based organizations in accordance with Executive Order 13279, Equal Protection of the Laws for Faith-Based and Community Organizations. All applicants should, however, be aware of restrictions on the use of direct financial assistance from the Department of Health and Human Services (DHHS) for inherently religious activities. Under the provisions of Title 45, Parts 74, 87, 92 and 96, organizations that receive direct financial assistance from DHHS under any DHHS program may not engage in inherently religious activities, such as worship, religious instruction, or proselytization as a part of the programs or services funded with direct financial assistance from DHHS. If an organization engages in such activities, it must offer them separately, in time or location, from the programs or services funded with direct DHHS assistance, and participation must be voluntary for the beneficiaries of the programs or services funded with such assistance. A religious organization that participates in the DHHS funded programs or services will retain its independence from Federal, State, and local governments, and may continue to carry out its mission, including the definition, practice, and expression of its religious beliefs, provided that it does not use direct financial assistance from DHHS to support inherently religious activities such as those activities described above. A faith-based organization may, however, use space in its facilities to provide programs or services funded with financial assistance from DHHS without removing religious art, icons, scriptures, or other religious symbols. In addition, a religious organization that receives financial assistance from DHHS retains its authority over its internal governance, and it may retain religious terms in its organization=s name, select its board members on a religious basis, and include religious references in its organization=s mission statements and other governing documents in accordance with all program requirements, statutes, and other applicable requirements governing the conduct of DHHS funded activities. For further guidance on the use of DHHS direct financial assistance see Title 45, Code of Federal Regulations, Part 87, Equal Treatment for Faith-Based Organizations, and visit the internet site:
Health Insurance Portability and Accountability Act Requirements
Recipients of this grant award should note that pursuant to the Standards for Privacy of Individually Identifiable Health Information promulgated under the Health Insurance Portability and Accountability Act (HIPAA) (45 CFR Parts 160 and 164) covered entities may disclose protected health information to public health authorities authorized by law to collect or receive such information for the purpose of preventing or controlling disease, injury, or disability, including, but not limited to, the reporting of disease, injury, vital events such as birth or death, and the conduct of public health surveillance, public health investigations, and public health interventions. The definition of a public health authority includes a person or entity acting under a grant of authority from or contract with such public agency. HHS/CDC considers this project a public health activity consistent with the Standards for Privacy of Individually Identifiable Health Information and CDC will provide successful recipients a specific grant of public health authority for the purposes of this project.
Release and Sharing of Data
The Data Release Plan is the Grantee's assurance that the dissemination of any and all data collected under the CDC data sharing agreement will be released as follows:
Applications must include a copy of the applicant's Data Release Plan. Applicants should provide CDC with appropriate documentation on the reliability of the data. Applications submitted without the required Plan may be ineligible for award. Award will be made when reviewing officials have approved an acceptable Plan. The successful applicant and the Program Manager will determine the documentation format. HHS/CDC recommends data is released in the form closest to micro data and one that will preserve confidentiality.
Note: Only proposals submitted to NCIPC for individual research projects of $500,000 or more in total (direct and indirect) costs per year require the applicant to include a data-sharing plan. If the proposed budget is below $500,000, a data sharing plan is not required.
Conference Disclaimer and Use of Logos
Disclaimer: Where a conference is funded by a grant or cooperative agreement, a subgrant or a contract the recipient must include the following statement on conference materials, including promotional materials, agenda, and internet sites:
�Funding for this conference was made possible [in part] by [insert grant or cooperative agreement award number] from the Centers for Disease Control and Prevention(CDC) or the Agency for Toxic Substances and Disease Registry (ATSDR) . The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.�
Logos: Neither the HHS nor the CDC (�CDC� includes ATSDR) logo may be displayed if such display would cause confusion as to the source of the conference or give the false appearance of Government endorsement. A non-federal entity�s unauthorized use of the HHS name or logo is governed by U.S.C. � 1320b-10, which prohibits the misuse of the HHS name and emblem in written communication. The appropriate use of the HHS logo is subject to the review and approval of the Office of the Assistant Secretary for Public Affairs (OASPA). Moreover, the Office of the Inspector General has authority to impose civil monetary penalties for violations (42 C.F.R. Part 1003). Neither the HHS nor the CDC logo can be used on conference materials under a grant, cooperative agreement, contract or co-sponsorship agreement without the expressed, written consent of either the Project Officer or the Grants Management Officer. It is the responsibility of the grantee (or recipient of funds under a cooperative agreement) to request consent for the use of the logo in sufficient detail to assure a complete depiction and disclosure of all uses of the Government logos, and to assure that in all cases of the use of Government logos, the written consent of either the Project Officer or the Grants Management Officer has been received.
Questions and Answers
What is meant by "project narrative" in the SF424 (R&R)?The "project narrative" attachment is required in the SF424 (R&R). As described in the SF424 (R&R) application guide, the project narrative should describe the relevance of the research. Using no more than two or three sentences, describe the relevance of this research to public health. In this section, be succinct and use plain language that can be understood by a general, lay audience.
Does the target community have to be a city? How small or how large does the target community need to be?
The FOA does not specify the location or size of a target community but the size of the target community needs to be sufficiently large enough to provide stable rates over time.
Can an observational study be proposed?
Experimental designs are strongly encouraged; however we realize that quasi-experimental designs, including time series may be appropriate if justified by the needs and constraints of a particular setting.
Is secondary data analysis of a previous trial appropriate for this application?
As long as youth violence outcomes have not already been analyzed, secondary data analysis of current or ongoing interventions designed to change other outcomes are permissible. Supplementing or extending data collection on youth violence outcomes already under investigation are not allowed.
CDC Home Page: http://www.cdc.gov
CDC Funding Web Page: http://www.cdc.gov/od/pgo/funding/FOAs.htm
CDC Forms Web Page:


text:
Vans Boys' Jeans
$48.00 $29.99 at Kohl's
The in crowd. These boys' Vans jeans are the latest and greatest in skater style. Superskinny cut offers the modern look and feel ...he wants. Pair these jeans with his favorite Vans tee for an A-plus outfit. Stretchy denim construction ensures lasting comfort. Details: 5-pocket Zipper fly Cotton/spandex Machine wash Imported Read More

subset: commoncrawl


text:
In the first week of November, the Food and Drug Administration issued recall of Vetsulin Insulin, a porcine based insulin produced by Intervet/Schering Plough. The recall notice can be viewed here: http://www.fda.gov/AnimalVeterinary/news
The recall was initiated due to an abnormal amount of crystalline zinc, or the longer acting, component of the insulin was found in the product. This improper formulation of the insulin can cause an unreliable response to the medication in the animal. Per Intervet/Schering Plough, while zinc is a normal part of the suspension, the inability to regulate an animal to the proper dose of insulin can cause unreliable glucose responses in patients.
The product has not been discontinued, but only limited supplies are available to the veterinary community. This means that if you have an animal regulated to Vetsulin insulin, if you have not already, you should open a dialogue with your veterinarian to be sure that you have a plan developed for your pet. There is a distinct possibility that you may need to start your animal on another type of insulin.
If you have a diabetic animal, you know that it can be quite hard to find the proper insulin dosing schedule to keep your pet healthy and happy. Switching an animal from one form of insulin to another is a task that must be undertaken carefully and with the support of a trusted veterinary professional. Thankfully there are many talented individuals as well as many different forms of insulin to use in the animal community.
For more information on Diabetes in animals, please: http://www.aspca.org/pet-care/cat-care/diabetes.html or any other reliable source of information on the internet.


text:
A N D G O phonics book 2a
Paperback, 18 Pages
Ships in 3-5 business days
Clever Phonics is as easy as 1, 2, 3!
Step 1. Children work their way through 1 phonics book at a time, each phonics book has 4/5 letter sounds in. At the end of each of these books is a recap, first with a visual clue, then without. The children will earn a sticker at each stage.
Each sound has a rhyme and an action.
Step 2. After the children have read that phonics book, they can move on to a corresponding 'I can read' book, where they will be able to start to merge the sounds together to learn to read.
Step 3. As the children progress through the books, they will meet 'the Clever Kids' who will be able to teach them digraphs such as 'Ch' Sh''Ai' etc...
For more information visit www.cleverphonics.com
There are no reviews for the current version of this product
There are no reviews for previous versions of this product
Product Details
- 9781291588040
- Copyright
- Jennifer Owen (Standard Copyright License)
- Edition
- First Edition
- Publisher
- Jennifer Owen
- Published
- October 24, 2013
- Language
- English
- Pages
- 18
- Binding
- Saddle-stitch Paperback
- Interior Ink
- Full color
- Weight
- 0.34 lbs.
- Dimensions (inches)
- 8.5 wide x 11 tall
Your notification has been sent
Lulu Staff has been notified of a possible violation of the terms of our Membership Agreement. Our agents will determine if the content reported is inappropriate or not based on the guidelines provided and will then take action where needed.
Thank you for notifying us. We will email you with the results and/or actions taken as a result of the investigation if you chose to receive confirmation.
We were unable to complete your request.
We were unable to complete your request.


text:
BOSTON (AP) - History was with Boston before the start of its AL division series against the Los Angeles Angels. The Red Sox need hits now.
If they don't get enough of them Sunday, their hopes for a third World Series championship in six years likely will be gone.
The Red Sox had just one run and eight hits in losing the first two games of the best-of-five series in Anaheim. They had won each of their last three division series against Los Angeles, taking nine of 10 games. Now they hope returning to Fenway Park will help.
Manager Terry Francona says his hitters are more comfortable at home.
Copyright 2015 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.


text:
CW12 Directory ResourceListing Details
Title: | The Hottest Models Of Sun Shades For 2011 |
URL: | http://yfsunglasses.com.au/mens-sunglasses.html |
Category: | Shopping |
Description: | The selling price selection for Fastrack eye gears in India is set concerning Rs. For this the polarized sun shades can be a very good option. Not each one particular can offer branded sun shades with price reduction tag. This write-up discusses numerous 7 acquiring information and facts. |
Meta Keywords: | buy christian dior sunglasses, buy chanel sunglasses, ladies sunglasses |
Meta Description: | Perfectly, my close friend, you can have all of that and extra! Some persons also go for the unisex vary of the Versace sun shades. |
Link Owner: | Rebecca Piper |
56608 | |
Pagerank: | N/A |


text:
Free next day collection from every store with Click+Collect
Pay Monthly Phones & SIMs
Tesco Mobile Pay monthly
Services & Support
Home Furniture
Brands & Characters
Shop F&F
Catalogue Number: 213-2438
Earn 35 Clubcard points
Sorry, this product is currently unavailable.
We've carefully chosen all our Tesco Partners, to give you even more choice when you shop with us online.
The Landmann Piccolino portable BBQ is perfect for enjoying a barbecue in your garden on the spur of the moment, or for taking with you to the beach or on a summer family outing.
Made from steel and fuelled by charcoal, the Piccolino has an enamelled lid and firebowl, and a chrome-plated cooking grill, with a surface diameter of 34cm. Rubberised clips keep the lid in place during transport and a ventilation disc deals with smoke and fumes. Stainless steel tongs are supplied that attach to the barbecue for convenience.
For outdoor use only. Do not leave barbecues unattended. Keep small children and pets clear of the cooking area.
Warning: Do not use barbecues in confined spaces, such as a tent. Risk of fatality from carbon monoxide poisoning, even when cooled down.
You have no recently viewed items
Follow us
We value your opinion


text:
Gainesville resident Deana Martin-Owens knows all too well the grief from losing a child is often debilitating and not many know what to do with it.
Already have an account? If so just LOG IN HERE.
Don't have an account? Sign up!
An ALL-INCLUSIVE Times 2 Go Subscription is required to continue reading more than 10 stories per month.
Print and digital packages, including an online-only option, begin at only $9.28 per month.
Having problems?
I've forgotten my username. Click here to retrieve it.
I've forgotten my password. Click here to reset it.
I never received a verfication message. The most likely culprit is a spam filter. If you don't find it there, we'll be happy to help. Send us a message and we'll work to resolve this quickly. We'll need your e-mail address or username to assist.
I have another issue. Write to us here. Please include your e-mail address and username.


text:
Senior Member
I have a question, when you decide to move his slow to E, have you think about how it will change his team fight style and ability. You kept saying how his target and himself gonna feel when he chases his target, but you did not mention his Q's another important function. His old play style in team fight is protecting ADC by keeping enemies slow, but I do not think his new abilities can do the same thing as well as before. Its CD is too long and the slow time is too short. And as a tank jungler, there is nothing else he can do. Unless we build more AP/AS items, and go to chase enemy ADC. His new abilities look like can do this well. But it change his play style too much, and I do not like it. I want to protect my allies and I enjoy that feeling, I think some other Skarner players have the same feeling. Please think about it, Riot. Thank you for reading and sorry for my bad English
Stampede EU
@RiotScruffy Like someone already mentioned, I hope you will be handing out refunds for the champion and the skins. I want nothing to do with this new Skarner, and this isn't even "content is subject to change" - this is me buying a car and then you giving me a god damn moped after 2 years.
I feel I should add that one of the things that I love most about Skarner (and the thing that makes him unique) is that he is a tanky champion that gets more durable with more AP. With 40% CDR, a few defensive items and a decent amount of AP and you have an extremely resilient little bug that does a fair amount of damage. The only reason this works is because of the AP scaling on both his W and his E. Are there any other tanky champs that work like that? Diana comes to mind, but it seems like she is picked mostly for her damage, not for her tankiness. I guess I feel like if these changes go through, my favorite part of my favorite champion is going to be taken out of the game. If the changes go live I'll give it a try and give it a fair chance. But I honestly don't believe that these changes are going to improve Skarner's win rate, which in turn means that his pick rate isn't going to improve. In my dream or dreams, this Skarner rework would be put on the table and an alternate rework would be developed using some of the communities ideas (mostly just tweaking his existing numbers) for the sake of comparison. Then the two could be compared and the best chosen between the two.
The whole new kid just makes Skarner the slowest reacting champion on the field. Q takes 3 uses for full effect. W takes 2 seconds for full effect. You never react to the fact that Skarner will be a jungler with zero tower pushing power. His whole Crystal Slash was designed to give him permaslow, thats why you have so little range with the slow, thats why you only make full damage after two hits and thats why you only slow after two hits. Now that you take that from him, we get nothing back for it. In fact you even take more from Skarner, no more sustain, lower atk speed, more mana and skill point costs. And you say he was to strong in your tests with stats that are closer to the actual numbers? Have you guys tested how Skarner is now; you might find that he is even now much overpowered and than give the whole project to someone else.


text:
Bring on the haters.
"An armed society is a polite society." Robert A. Heinlein "After a shooting spree, they always want to take the guns away from the people who didn't do it. I sure as hell wouldn't want to live in a society where the only people allowed guns are the police and the military." William S. Burroughs
Join FirearmsTalk.com Today - It's Free!
Are you a firearms enthusiast? Then we hope you will join the community. You will gain access to post, create threads, private message, upload images, join groups and more. Firearms Talk is owned and operated by fellow firearms enthusiasts. We strive to offer a non-commercial community to learn and share information.
Join FirearmsTalk.com Today! - Click Here
I love how the laser falls off...lol
dumb a$$ video
Hilarious video. There's another "table top review" of the Ninja Glock that came out before Shooting the Ninja Glock.
"Ideology deludes, inspires dishonesty, and breeds fanaticism. Facts, experience, and logic are much better at leading you to the truth." "Despite the conviction and seeming depth of knowledge with which ideologues speak, they are intellectual weaklings--joiners--who defer to systems of belief and charismatic gurus for their ideas." -- Daniel J. FlynnGOA
How did he get the scope on it?
Effin hilarious. Love it
good for a few laughs, thanks for sharing.
Now that was damn creative work. I love that the scope can see into the future AND the past, because the previous models were one or the other. A fantastic improvement. JD
NRA LIFE Member, GSSF MEMBER, Custom Fusion CCO 9mm & 38 SUPER Race Gun, Nighthawk Lady Hawk 9mm Custom & 38Super, Kimber Pro Aegis II Bobtail, Glock G19 Gen 4, G17, G26 G4, G34, Sig P238,RIA 38 Super, Timber Wolf-AA 22LR, GSG-1911-22LR.
Thanks for that, utf59. Great, just great!
______ The biggest issue with assembling an AR isn't so much getting the parts together right - it's getting the right parts together. ________________________________________ US Army 1966-69, VFW Life Member, Retired Geek


text:
- Shopping Bag ( 0 items )
From the Publisher
Published Reviews of the 6th Edition"This book is excellent, no nonsense, to the point, what you need to know is this. If only all books were as easy to learn from."
Sphincter, Liverpool Medical School Gazette
"The Lecture Notes series gets better and better and this is no exception [...] It is a joy to use and I would use it in preference to other 'baby' final year revision texts on the market [...] There is a small and illuminating chapter on the eye, and how to successfully focus an opthalmoscope. Surely, that in itself is worth the cover price."
GKT Gazette, December 2004
"The logical, well laid-out approach taken by this book really does facilitate learning. Thoroughly recommended."
University of Wales College of Medicine Student Gazette
"It is a useful refresher of information that is, or perhaps should be, deep down there somewhere.The book is positively crammed with information."
2nd Opinion
"It will be a good base for revision for any organized dudes out there, but it will also be a good oh-my-god-the-exams-is-in-half-an-hour last minute revision textbook. So yeah, I totally recommend it, but only for 3rd/4th years."
2nd Year Medical Student, Liverpool Medical School
Sphincter, December 2003
"...this book tackles the vast subject that is clinical medicine in a matter of fact, easy to learn way. It does exactly what it says on the tin: a no-nonsense overview of clinical medicine, perfect in the run up to finals."
Oxford Medical School Gazette, vol. 54 (1)
"This book more than lives up to the other popular books in the same 'lecture notes' series with its clear, concise, no-nonsense format [...] ideal for revision."
North Wing, Sheffield Medics Magazine, Winter 2004